Johnson & Johnson fined $8 billion for hiding breast growing side effect in males of a drug

Johnson & Johnson must pay $8 billion in punitive damages to a man who previously won $680,000 over his claims that it failed to warn that young men using its antipsychotic drug Risperdal could grow breasts, a Philadelphia jury said on Tuesday.

J&J said the award was grossly disproportionate with the initial compensatory award in this case, and the company is confident it will be overturned. It added that the jury in the case had not been allowed to hear evidence of Risperdal’s benefits.

Plaintiffs claim that J&J failed to warn of the risk of gynecomastia, the development of enlarged breasts in males, associated with Risperdal, which they say the company marketed for unapproved uses with children.

In his lawsuit, Murray, now 26, alleged that he developed breasts after his doctors began prescribing him Risperdal off-label in 2003 after a psychologist diagnosed him with autism spectrum disorder. Doctors are allowed to prescribe medicines as they see fit, while companies are only allowed to promote their drugs for approved uses.

A jury in 2015 awarded Murray $1.75 million after finding J&J was negligent in failing to warn of the risk of gynecomastia. A state appeals court upheld the verdict in February 2018 but reduced it to $680,000.

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Stay Connected

2,038FansLike
92FollowersFollow
36FollowersFollow
- Advertisement -

Latest Articles